Aurevia Polandsp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Aurevia Poland is a consulting company that provides services in medtech regulatory compliance and clinical research, supporting pharmaceuticals, advanced therapy medicinal products (ATMPs), biologics, medical devices, and in vitro diagnostic (IVD) devices. They offer full-service clinical research organization (CRO) services and quality assurance and regulatory affairs services throughout the lifecycle of medical devices. Additionally, Aurevia Academy provides professional training in quality assurance, regulatory affairs, and clinical research.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Need support with EUDAMED?
As of 28 May 2026, mandatory use of key EUDAMED modules has started. Contact us for support with the EUDAMED registration process.
Do you know your bridges?
This bridge is more than a landmark. It's also a fun challenge waiting for you at the Aurevia booth (E:16) during NLSDays 2026 in Stockholm, Sweden.
Why are Aurevia and RAPS collaborating on the Medtech Compliance Forum?
Why are Aurevia and RAPS collaborating on the Medtech Compliance Forum? Find out what it offers regulatory professionals and medtech companies.
Change begins with the world's best question
Anna-Karin Alm, Head of QARA at Aurevia, explores why successful regulatory change is about more than compliance, documentation, and new processes.
Clinical evaluation course: 09 October
Our clinical evaluation course, in collaboration with Swedish Medtech, provides knowledge on the clinical evidence requirements for medical devices.
Updated ISO 14155:2026 Standard for Medical Device Studies
The updated ISO 14155:2026 standard for clinical investigations has now been published. However, the new version is not yet harmonized with MDR.
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-01-15. Active
04 2490 0005 0000 4600 4227 9162- 10 2490 0005 0000 4600 9862 9749
- 20 2490 0005 0000 4600 5381 3920
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
12 public aid cases recorded, with a total value of $248,711.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Feb 17, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $43,924$43,924 | Górnośląski Akcelerator Przedsiębiorczości Rynkowej sp. z o.o. | |
| Apr 26, 2023 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $493$493 | Prezydent Miasta Tychy | |
| Nov 10, 2021 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $12,473$12,473 | Górnośląski Akcelerator Przedsiębiorczości Rynkowej sp. z o.o. |
Tenders
1 tender recorded as contractor, with a total value of $285,896.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Oct 8, 2024 | Wsparcie Sponsora w przeprowadzeniu niekomercyjnego badania klinicznego (tzw. usługa CRO), w ramach realizowanego projektu: pt. „Ocena skuteczności i bezpieczeństwa stosowania jodowych środków kontrastowych w mammografii spektralnej w korelacji z badaniem rezonansu magnetycznego piersi u chorych z podejrzeniem raka piersi.”, dla Uniwersytetu Jagiellońskiego – Collegium Medicum w Krakowie. | $285.9K$285,896 | Uniwersytet Jagielloński - Collegium Medicum |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The President of the Management Board independently; a member of the management board who is not the President of the Management Board jointly with another member of the management board or with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Aurevia Oy | 150 | $2,025.93 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Sidlysp. z o.o. | $4,977,649.42 | sidly.eu | ||
| Scope FluidicsS.A. | $3,082,936.61 | scopefluidics.com | ||
| Clinchoicesp. z o.o. | $2,048,208.30 | clinchoice.com | ||
| Eurxsp. z o.o. | $1,644,555.44 | eurx.com.pl | ||
| Medsource Polskasp. z o.o. | $1,620,329.12 | medsource.com.pl | ||
| Aslab ScienceP.S.A. | $1,504,132.17 | aslabsci.com | ||
| BiokineticaS.A. | $1,292,838.89 | biokinetica.com | ||
| CTI Clinical Trial And Consulting Services Polandsp. z o.o. | $527,145.56 | ctifacts.com | ||
| Proper Medical Writingsp. z o.o. | $514,848.41 | propermedicalwriting.com | ||
| CCTSsp. z o.o. | $281,193.31 | ccts.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-01-10 | Name change (Clinical Consulting → Aurevia Poland) | |
| 2023-10-23 | PKD change (Removed: 68.20.Z, 72.11.Z, 72.20.Z, 73.20.Z, 77.21.Z, 86.21.Z, 86.22.Z, 86.90.D, 86.90.E; Added: 68, 72, 73, 77, 86) | |
| 2021-01-21 | PKD change (Removed: 68, 72, 73, 77, 86; Added: 68.20.Z, 72.11.Z, 72.19.Z, 72.20.Z, 73.20.Z, 77.21.Z, 86.21.Z, 86.22.Z, 86.90.D, 86.90.E) | |
| 2018-09-27 | Share capital change (5,000.00 PLN → 7,500.00 PLN) | |
| 2015-08-01 | Business resumed |
FAQ
Last updated: 2026-10-07